Cowen analyst, Joshua Jennings, reiterated his Outperform rating on shares of Johnson & Johnson (NYSE: JNJ) after the FDA announced ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE